ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: PlaceboBiological: Risankizumab
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 964
- Registration Number
- NCT03675308
- Locations
- 🇮🇹
Duplicate_Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 207799, Modena, Emilia-Romagna, Italy
🇺🇸Medvin Clinical Research /ID# 211127, Whittier, California, United States
🇺🇸June DO, PC /ID# 208915, Lansing, Michigan, United States
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
- Conditions
- Psoriatic Arthritis (PsA)
- Interventions
- Biological: Placebo
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 444
- Registration Number
- NCT03671148
- Locations
- 🇺🇸
Arthritis and Rheumatology /ID# 169438, Atlanta, Georgia, United States
🇺🇸Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 166681, Skokie, Illinois, United States
🇺🇸DM Clinical Research /ID# 208350, Tomball, Texas, United States
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 272
- Registration Number
- NCT03661138
- Locations
- 🇯🇵
Fukuyama City Hospital /ID# 206761, Fukuyama-shi, Hiroshima, Japan
🇯🇵Nagoya City University Hospital /ID# 207566, Nagoya shi, Aichi, Japan
🇯🇵Central Clinic /ID# 206558, Nagoya-shi, Aichi, Japan
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 272
- Registration Number
- NCT03659669
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center /ID# 206962, Tel Aviv-Yafo, Tel-Aviv, Israel
🇮🇱Rabin Medical Center /ID# 206961, Petakh Tikva, Israel
🇮🇱Hadassah /ID# 207898, Jerusalem, Israel
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 522
- Registration Number
- NCT03653026
- Locations
- 🇺🇸
TLC Clinical Research Inc /ID# 216831, Los Angeles, California, United States
🇺🇸Universal Axon Clinical Research /ID# 213462, Doral, Florida, United States
🇺🇸Gastrointestinal Biosciences Clinical Trials, LLC /ID# 205314, Los Angeles, California, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 32
- Registration Number
- NCT03646604
- Locations
- 🇺🇸
Children's Hospital Los Angeles /ID# 206042, Los Angeles, California, United States
🇺🇸Cincinnati Children's Hospital /ID# 207071, Cincinnati, Ohio, United States
🇺🇸Beach Pediatrics /ID# 207834, Huntington Beach, California, United States
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 132
- Registration Number
- NCT03639194
- Locations
- 🇺🇸
UH Cleveland Medical Center /ID# 207561, Cleveland, Ohio, United States
🇺🇸The Ohio State University /ID# 207552, Columbus, Ohio, United States
🇺🇸Highlands Oncology Group, PA /ID# 207176, Springdale, Arkansas, United States
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 61
- Registration Number
- NCT03625505
- Locations
- 🇺🇸
Northwestern Memorial Hospital /ID# 200230, Chicago, Illinois, United States
🇺🇸Sylvester Comprehensive Cancer /ID# 200268, Miami, Florida, United States
🇺🇸David Geffen School of Medicin /ID# 200166, Los Angeles, California, United States
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 912
- Registration Number
- NCT03607422
- Locations
- 🇺🇸
Dermatology Treatment and Research Center, PA /ID# 205473, Dallas, Texas, United States
🇺🇸Arkansas Research Trials /ID# 218469, North Little Rock, Arkansas, United States
🇺🇸Floridian Clinical Research /ID# 207433, Miami Lakes, Florida, United States
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 169
- Registration Number
- NCT03595059
- Locations
- 🇺🇸
AdventHealth Orlando /ID# 227242, Orlando, Florida, United States
🇺🇸Duplicate_Henry Ford Hospital /ID# 226852, Detroit, Michigan, United States
🇨🇦University Health Network_Princess Margaret Cancer Centre /ID# 204539, Toronto, Ontario, Canada